Research programme: drug discovery - GlaxoSmithKline/Ligand
Latest Information Update: 18 Apr 2011
Price :
$50 *
At a glance
- Originator GlaxoSmithKline; Pharmacopeia Drug Discovery
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammatory pain; Pain; Respiratory tract disorders
Most Recent Events
- 31 Dec 2010 Discontinued - Preclinical for Inflammatory pain in USA (unspecified route)
- 31 Dec 2010 Discontinued - Preclinical for Pain in USA (unspecified route)
- 31 Dec 2010 Discontinued - Preclinical for Respiratory tract disorders in USA (unspecified route)